N-able Inc Ordinary Shares NABL 深 沪
已收盘 12-19 16:00:00 美东时间
7.64
-0.030
-0.39%
华盛通- 最 高7.725
- 今 开7.68
- 成交量 154.28万股
- 最 低 7.565
- 昨 收 7.67
- 总市值 14.21亿
- 52周最高 10.408
- 市盈率 静 46.50
- 换手率 0.83%
- 52周最低 6.07
- 委 比 -73.01%
- 总股本 1.86亿
- 历史最高 15.85
- 量 比 1.99
- 振 幅 2.09%
- 历史最低 6.07
- 每 手 1
- 风险率 0.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Security Tech Check-In: Analyst Insights From 12 Companies Ahead Of The 'Quiet Period'
Needham analysts met with 12 companies before quiet period. Ratings and price targets by analyst Mike Cikos.
12-19 03:38
N-able Empowers DoD Contractors with New Cybersecurity Tools for Stronger Business Resilience
N-able, Inc. (NYSE:NABL), a global software company delivering an end-to-end cyber resilience platform, today announced the public preview of a version of its N-able N-central unified endpoint management (UEM) solution
11-18 19:09
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
N-able shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 sales guidance above estimates. Also, the company raised its FY25 sales guidance above estimates.
N-able shares are trading higher after the company reported better-than-expecte...
11-06 22:24
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
N-Able shares are trading higher after the company reported better-than-expected Q2 financial results, issued Q3 sales guidance above estimates, and raised its FY25 sales guidance above estimates.
N-Able shares are trading higher after the company reported better-than-expecte...
08-07 21:12
N-able Sees Q3 Sales $127.000M-$128.000M vs $125.138M Est
N-able (NYSE:NABL) sees Q3 sales of $127.000 million-$128.000 million vs $125.138 million analyst estimate.
08-07 19:03
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
